Silence Therapeutics PLCOTC Pink - Current Information:SLNCF
- LAST PRICE5.5000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots2.0200/ 1
- Ask / Lots6.5000/ 2
- Open / Previous Close--- / 5.5000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Nov 20, 2024
DJ Silence Therapeutics Price Target Maintained With a $75.00/Share by HC Wainwright & Co., from 4:57AM ET on Wednesday Nov 20, 2024 by Dow Jones
4:57AM ET on Wednesday Nov 20, 2024 by Dow Jones
Nov 18, 2024
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting, from 2:30PM ET on Monday Nov 18, 2024 by Dow Jones
2:30PM ET on Monday Nov 18, 2024 by Dow Jones
Nov 15, 2024
DJ Silence Therapeutics Price Target Maintained With a $75.00/Share by HC Wainwright & Co., from 2:41PM ET on Friday Nov 15, 2024 by Dow Jones
2:41PM ET on Friday Nov 15, 2024 by Dow Jones
Nov 14, 2024
DJ Silence Therapeutics Is Maintained at Buy by Chardan Capital, from 4:57PM ET on Thursday Nov 14, 2024 by Dow Jones
4:57PM ET on Thursday Nov 14, 2024 by Dow JonesPress Release: Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Silence Therapeutics PLC | 358.3M | -13.6x | --- |
Silence Therapeutics PLC | 358.3M | -6.3x | --- |
OmniAb Inc | 454.9M | -6.2x | --- |
Foghorn Therapeutics Inc. | 429.2M | -4.0x | --- |
Tango Therapeutics Inc | 389.9M | -3.2x | --- |
Zenas Biopharma Inc | 415.4M | -3.3x | --- |
Company Information
Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. It also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.
Contact Information
- Headquarters
- 72 Hammersmith RoadLONDON, United Kingdom W14 8TH
- Phone
- 203-457-6900
- Fax
- 795-731-8494
Executives
- Non-Executive Chairman of the Board
- Iain Ross
- President, Chief Executive Officer, Executive Director
- Craig Tooman
- Chief Technical Operations Officer
- J.P Gabriel
- Chief Scientific Officer
- Marie Lindholm
- Chief Medical Officer
- Curtis Rambarn
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $358.3M |
|---|---|
Revenue (TTM) | $22.5M |
Shares Outstanding | 46.7M |
Silence Therapeutics PLC does not pay a dividend. | |
Beta | 0.28 |
EPS | $-0.41 |
Book Value | $0.18 |
P/E Ratio | -13.6x |
Price/Sales (TTM) | 15.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -270.81% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
